(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Israeli naval intelligence reduces Iranian threat to Strait of Hormuz - 2Vote In favor of Your Favored Menial helper Administration
- 3Police investigate Lahav 433 officer accused of sexually harassing subordinate policewoman
- 4Famous Kitchen Finishing Styles For 2024
- 5Figure out How to Alter Your Volvo XC40 for Further developed Solace
- What is the Significant Tech Expertise to Master Today?
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- Shadow Cats: The Elusive Leopards Surviving Against Impossible Odds
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Obamacare enrollment declines as US subsidies expire
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- Bombardier Global 8000 Enters Service
